Benitec Biopharma stock soars to 52-week high of $13.32

Published 11/03/2025, 20:22
Benitec Biopharma stock soars to 52-week high of $13.32

Benitec Biopharma Inc. (BNTC), a biotechnology company with a market capitalization of $288 million, has reached a remarkable milestone, with its stock price hitting a 52-week high of $13.32. According to InvestingPro analysis, the stock appears overvalued at current levels, though analyst price targets range from $17 to $35. This peak reflects a significant surge in investor confidence and market performance for the biotechnology firm, which specializes in developing gene-silencing therapies. Over the past year, Benitec Biopharma has seen an impressive 147% return, with particularly strong momentum shown by its 45% gain over the past six months. The company maintains a healthy financial position with a current ratio of 25.48 and relatively low market volatility (beta: 0.92). InvestingPro subscribers have access to 8 additional key insights about BNTC’s financial health and growth prospects, along with comprehensive Pro Research Reports that transform complex Wall Street data into actionable intelligence.

In other recent news, Benitec BioPharma has been active with several significant developments. The company shared promising interim results from its Phase 1b/2a trial of BB-301, aimed at treating Oculopharyngeal Muscular Dystrophy (OPMD), with subjects showing notable improvements in swallowing function. In addition, Benitec presented interim data from this study at the Muscular Dystrophy Association Clinical and Scientific Conference. Analysts from H.C. Wainwright maintained a Buy rating with a $28 price target, reflecting confidence in the ongoing trials and the potential of BB-301. Meanwhile, Citizens JMP reiterated a Market Outperform rating with an $18 target, highlighting progress in the FiH OPMD trial.

Furthermore, Benitec announced key executive team changes, appointing Sophie Mukadam as the new Chief Operating Officer and Megan Boston as the Chief Financial Officer, effective January 1, 2025. The company also adjusted compensation packages for its leadership, granting stock options to its CEO, Dr. Jerel Banks, and Ms. Boston. These corporate changes are part of Benitec’s strategy to align with market practices and incentivize its leadership team. Investors are closely monitoring these developments as Benitec continues to advance its clinical trials and strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.